The Integrated Shield Upgrade with a Loaded Condition
Mdm Lim, 48, is a regional sales manager earning $150,000 a year. She has hypertension controlled with one medication and a benign thyroid nodule biopsied three years ago. Her current cover is MediShield Life plus a Class B1 Integrated Shield Plan without a rider, paid largely from MediSave. An adviser proposes upgrading to a private-hospital plan with a rider that carries a 5% co-payment; the estimated extra cost is $3,200 cash a year plus MediSave. She also has employer group hospitalisation cover with a $50,000 annual limit, which stops when she leaves. Mdm Lim wants to know whether the upgrade is worth it, and whether she should drop the rider to reduce cost. She says her thyroid is 'not a real condition' and asks whether she needs to mention it again because it was disclosed years ago.
1. Evaluate the proposed upgrade and the rider decision.
Read the worked answer
The upgrade buys access to private hospitals and greater choice of doctors, but it also brings higher and age-increasing premiums. The rider with 5% co-payment reduces the deductible and co-insurance burden for large bills while leaving Mdm Lim with a share of the cost; dropping the rider lowers premiums but increases her out-of-pocket exposure if she is hospitalised. The comparison should be based on her likely claim pattern, her cash flow and her preference for public versus private care. Her employer cover has a $50,000 annual limit and is not portable, so it cannot be the foundation of a long-term plan. If she values private care and can absorb future premium increases, the upgrade may be suitable. If not, keeping the B1 plan and building a health reserve is defensible. The adviser should show projected premiums at older ages, not just the first-year cost.
2. What are Mdm Lim's disclosure obligations, and how should the adviser handle the thyroid nodule?
Read the worked answer
Mdm Lim must answer the insurer's questions fully and honestly. A benign thyroid nodule is a material medical fact, and the fact that it was disclosed to a previous insurer or years ago does not automatically transfer to a new application. Non-disclosure can allow the insurer to avoid the policy or decline a related claim. The adviser should not describe the condition as 'not real' or coach her to leave it out. Instead, obtain the biopsy report and specialist follow-up notes, submit them with the application and let the underwriter decide. The likely outcomes are standard terms, a loading or a thyroid-specific exclusion. If an exclusion is imposed, explain its effect in plain language and record that Mdm Lim accepted it. If she refuses to disclose, the adviser should decline to submit the application.
3. How should employer group coverage affect the recommendation, and what affordability check is needed?
Read the worked answer
Employer group cover is a useful supplement but a weak foundation: it is annual, limited to $50,000, and ends on resignation or retirement. Mdm Lim should not drop her individual Integrated Shield Plan because of it. The adviser should compare the group plan's annual limit, panel restrictions and exclusions with her individual plan, and treat the group cover as reducing only the short-term need for a rider rather than replacing it. Affordability must be tested beyond year one: the $3,200 cash cost plus MediSave withdrawal may rise materially with age, and MediSave withdrawal limits mean part of the premium will always be cash. A reasonable check is whether the total health premium remains below a stated percentage of her income after retirement, and whether she has a separate fund for premiums in later life.